Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Investment analysts at Jefferies Financial Group lifted their Q1 2022 earnings estimates for shares of Ultragenyx Pharmaceutical in a research report issued on Monday, April 25th. Jefferies Financial Group analyst M. Raycroft now forecasts that the biopharmaceutical company will post earnings per share of ($1.48) for the quarter, up from their previous forecast of ($1.49). Jefferies Financial Group also issued estimates for Ultragenyx Pharmaceutical’s Q2 2022 earnings at ($1.45) EPS, Q3 2022 earnings at ($1.36) EPS, Q4 2022 earnings at ($1.30) EPS, FY2022 earnings at ($5.57) EPS, FY2023 earnings at ($3.44) EPS and FY2024 earnings at ($2.83) EPS.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) last posted its earnings results on Thursday, February 10th. The biopharmaceutical company reported ($1.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.47). The company had revenue of $83.39 million for the quarter, compared to the consensus estimate of $83.68 million. Ultragenyx Pharmaceutical had a negative return on equity of 44.24% and a negative net margin of 129.20%. Ultragenyx Pharmaceutical’s quarterly revenue was down 8.9% compared to the same quarter last year. During the same quarter last year, the business earned ($1.34) EPS.
Ultragenyx Pharmaceutical stock opened at $70.74 on Wednesday. The company has a market cap of $4.91 billion, a P/E ratio of -10.54 and a beta of 1.68. Ultragenyx Pharmaceutical has a one year low of $61.21 and a one year high of $119.54. The stock’s 50 day moving average is $71.79.
In related news, EVP Camille L. Bedrosian sold 1,657 shares of Ultragenyx Pharmaceutical stock in a transaction on Sunday, January 30th. The stock was sold at an average price of $66.30, for a total transaction of $109,859.10. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Thomas Richard Kassberg sold 10,281 shares of Ultragenyx Pharmaceutical stock in a transaction on Friday, March 11th. The stock was sold at an average price of $67.01, for a total value of $688,929.81. The disclosure for this sale can be found here. Insiders sold a total of 24,421 shares of company stock valued at $1,613,909 over the last three months. Insiders own 6.70% of the company’s stock.
Several institutional investors have recently made changes to their positions in RARE. Dimensional Fund Advisors LP grew its stake in Ultragenyx Pharmaceutical by 32.9% in the third quarter. Dimensional Fund Advisors LP now owns 226,256 shares of the biopharmaceutical company’s stock valued at $20,401,000 after acquiring an additional 56,065 shares during the period. Allianz Asset Management GmbH lifted its holdings in shares of Ultragenyx Pharmaceutical by 133.6% in the third quarter. Allianz Asset Management GmbH now owns 43,361 shares of the biopharmaceutical company’s stock valued at $3,911,000 after purchasing an additional 24,799 shares in the last quarter. Virginia Retirement Systems ET AL lifted its holdings in shares of Ultragenyx Pharmaceutical by 13.0% in the fourth quarter. Virginia Retirement Systems ET AL now owns 13,900 shares of the biopharmaceutical company’s stock valued at $1,169,000 after purchasing an additional 1,600 shares in the last quarter. Oppenheimer Asset Management Inc. bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at about $334,000. Finally, Rock Springs Capital Management LP lifted its holdings in shares of Ultragenyx Pharmaceutical by 72.3% in the third quarter. Rock Springs Capital Management LP now owns 801,109 shares of the biopharmaceutical company’s stock valued at $72,252,000 after purchasing an additional 336,109 shares in the last quarter. 97.52% of the stock is owned by institutional investors and hedge funds.
Ultragenyx Pharmaceutical Company Profile (Get Rating)
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
- Get a free copy of the StockNews.com research report on Ultragenyx Pharmaceutical (RARE)
- Las Vegas Sands Stock Could be a Winning Bet Down Here
- Newmont Corporation is the Same as It’s Always Been Which is Why It’s a Buy
- Simpson Manufacturing Co. Hits The Nail On The Head, Again
- The Sherwin-Williams Company Bottoms Above Institutional Support
- What To Make Of Activision Blizzard (NASDAQ: ATVI)
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.